Oral cyclophosphamide and oral hydroxyurea in the treatment of hormone refractory prostate cancer in rats

H. Naik, J. Lehr, A. Akhtar, Kenneth Pienta

Research output: Contribution to journalArticle

Abstract

Hormone refractory prostate cancer is a fatal disease and currently no standard cytotoxic chemotherapy exists for prostate cancer. The recent use of prostate specific antigen as an endpoint for clinical trial has resulted in the ability to test the activity of chemotherapy agents in a quick manner. The aim of this study was to investigate the activity of the oral combination of two familiar agents, cyclophosphamide and hydroxyurea, against hormone refractory prostate cancer. In vitro studies demonstrated that hydroxyurea was more active than cyclophosphamide against the anaplastic Dunning rat prostate cancer cell line, Mat-LyLu. In vivo experiments, however, demonstated cyclophosphamide to be superior to hydroxyurea. The combination of both agents failed to enhance inhibition of subcutaneously implanted Mat-LyLu cells. A human trial of oral cyclophosphamide using prostate specific antigen as an intermediate endpoint may be warranted.

Original languageEnglish (US)
Pages (from-to)2681-2684
Number of pages4
JournalAnticancer Research
Volume14
Issue number6 B
StatePublished - 1994
Externally publishedYes

Fingerprint

Hydroxyurea
Cyclophosphamide
Prostatic Neoplasms
Hormones
Prostate-Specific Antigen
Drug Therapy
Therapeutics
Clinical Trials
Cell Line

Keywords

  • Cyclophosphamide
  • Hormone refractory prostate cancer
  • Hydroxyurea
  • Rat

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Oral cyclophosphamide and oral hydroxyurea in the treatment of hormone refractory prostate cancer in rats. / Naik, H.; Lehr, J.; Akhtar, A.; Pienta, Kenneth.

In: Anticancer Research, Vol. 14, No. 6 B, 1994, p. 2681-2684.

Research output: Contribution to journalArticle

@article{cbb69af8776c4e409eb1b1765bab4839,
title = "Oral cyclophosphamide and oral hydroxyurea in the treatment of hormone refractory prostate cancer in rats",
abstract = "Hormone refractory prostate cancer is a fatal disease and currently no standard cytotoxic chemotherapy exists for prostate cancer. The recent use of prostate specific antigen as an endpoint for clinical trial has resulted in the ability to test the activity of chemotherapy agents in a quick manner. The aim of this study was to investigate the activity of the oral combination of two familiar agents, cyclophosphamide and hydroxyurea, against hormone refractory prostate cancer. In vitro studies demonstrated that hydroxyurea was more active than cyclophosphamide against the anaplastic Dunning rat prostate cancer cell line, Mat-LyLu. In vivo experiments, however, demonstated cyclophosphamide to be superior to hydroxyurea. The combination of both agents failed to enhance inhibition of subcutaneously implanted Mat-LyLu cells. A human trial of oral cyclophosphamide using prostate specific antigen as an intermediate endpoint may be warranted.",
keywords = "Cyclophosphamide, Hormone refractory prostate cancer, Hydroxyurea, Rat",
author = "H. Naik and J. Lehr and A. Akhtar and Kenneth Pienta",
year = "1994",
language = "English (US)",
volume = "14",
pages = "2681--2684",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 B",

}

TY - JOUR

T1 - Oral cyclophosphamide and oral hydroxyurea in the treatment of hormone refractory prostate cancer in rats

AU - Naik, H.

AU - Lehr, J.

AU - Akhtar, A.

AU - Pienta, Kenneth

PY - 1994

Y1 - 1994

N2 - Hormone refractory prostate cancer is a fatal disease and currently no standard cytotoxic chemotherapy exists for prostate cancer. The recent use of prostate specific antigen as an endpoint for clinical trial has resulted in the ability to test the activity of chemotherapy agents in a quick manner. The aim of this study was to investigate the activity of the oral combination of two familiar agents, cyclophosphamide and hydroxyurea, against hormone refractory prostate cancer. In vitro studies demonstrated that hydroxyurea was more active than cyclophosphamide against the anaplastic Dunning rat prostate cancer cell line, Mat-LyLu. In vivo experiments, however, demonstated cyclophosphamide to be superior to hydroxyurea. The combination of both agents failed to enhance inhibition of subcutaneously implanted Mat-LyLu cells. A human trial of oral cyclophosphamide using prostate specific antigen as an intermediate endpoint may be warranted.

AB - Hormone refractory prostate cancer is a fatal disease and currently no standard cytotoxic chemotherapy exists for prostate cancer. The recent use of prostate specific antigen as an endpoint for clinical trial has resulted in the ability to test the activity of chemotherapy agents in a quick manner. The aim of this study was to investigate the activity of the oral combination of two familiar agents, cyclophosphamide and hydroxyurea, against hormone refractory prostate cancer. In vitro studies demonstrated that hydroxyurea was more active than cyclophosphamide against the anaplastic Dunning rat prostate cancer cell line, Mat-LyLu. In vivo experiments, however, demonstated cyclophosphamide to be superior to hydroxyurea. The combination of both agents failed to enhance inhibition of subcutaneously implanted Mat-LyLu cells. A human trial of oral cyclophosphamide using prostate specific antigen as an intermediate endpoint may be warranted.

KW - Cyclophosphamide

KW - Hormone refractory prostate cancer

KW - Hydroxyurea

KW - Rat

UR - http://www.scopus.com/inward/record.url?scp=0028630597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028630597&partnerID=8YFLogxK

M3 - Article

C2 - 7872701

AN - SCOPUS:0028630597

VL - 14

SP - 2681

EP - 2684

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 B

ER -